At the MoneyHow many at the money convertible debenture issues do you ever see since we're now at $0.40 per share? Given the huge number of shares just traded at this price it signals a serious rise to this level. Not surprised as Tigris is a CONFIRMATORY trial with FDA Breakthrough designation and with 71 patients exceeding expectations already and only 19 to go to the interim point of 90 patients. As MM (and Paradigm) say we're at virtual 100% certainty. Baxter will pony up the second tranche at the interim point - the fact we've only raised $5 million for this raise just illustrates that point.
Time to get the champagne chilling so we're ready to pop the cork shortly. Been a long road for all the real shareholders here. But the upcoming reward will more than justify the long and rocky road we've had to get here.